NextCell Pharma AB

65G

Company Profile

  • Business description

    NextCell Pharma AB is a Swedish clinical-stage biotechnology company developing mesenchymal stromal cell (MSC)-based therapies for autoimmune and inflammatory diseases, with a primary focus on Type 1 Diabetes. Its key product candidate, ProTrans, is designed to preserve insulin-producing capacity in Type 1 Diabetes patients, while the company also operates Cellaviva, Scandinavia's private stem-cell bank, and QVance, which provides analytical and quality-control services for therapy medicinal products. It's operations are organized into three business areas: ProTrans (cell therapy development), Cellaviva (stem-cell banking), and QVance (ATMP analytical services). The company's activities are concentrated in Sweden and the Nordic region.

  • Contact

    Karolinska Institutet Science Park
    Halsovagen 7
    Huddinge14157
    SWE

    T: +46 87355595

    https://www.nextcellpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    24

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.6095.80-1.07%
CAC 408,189.9543.120.53%
DAX 4025,930.50194.260.75%
Dow JONES (US)50,198.17561.25-1.11%
FTSE 10010,550.400.77-0.01%
HKSE22,841.62453.13-1.95%
NASDAQ24,429.88101.500.42%
Nikkei 22559,444.21419.930.71%
NZX 50 Index14,247.2517.04-0.12%
S&P 5007,323.6316.90-0.23%
S&P/ASX 2008,730.4091.40-1.04%
SSE Composite Index3,577.6210.21-0.28%

Market Movers